Cytogen is actively seeking collaborative and licensing initiatives to access complementary clinical-stage and marketed products. We have a number of key assets to offer prospective partners, including:
an experienced senior management team,
a growing commercial presence in the U.S. oncology market, and
a successful track record for bringing products through clinical development to the market.
In addition, we have developed technology that is available for strategic partnerships and out-licensing. For example, we have identified peptide sequences that enhance transport across the gastro-intestinal tract (GIT) which we believe may be a novel approach to the oral delivery of macromolecules, including proteins and peptides, using peptide-coated nanoparticles.
